Author

Tetsuhiko Taira

Institution: Sagara Hospital

Observed institution: Sagara Hospital

ORCID: 0000-0002-3091-8168

Observed ORCID: 0000-0002-3091-8168

OpenAlex ID: A5012279869

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 256

Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial

2024 · Eriko Tokunaga, Hiroji Iwata, et al. · Breast Cancer · 16

Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study

2022 · Haruru Kotani, Norikazu Masuda, et al. · Breast Cancer · 9

Wearable-derived physical activity monitoring with AI-based detection of treatment-related adverse events during neoadjuvant chemotherapy for early breast cancer: TRACK-BC.

2026 · Nobuhiro Shibata, Yukinori Ozaki, et al. · Journal of Clinical Oncology

Works count: 4

Citation count: 281

H-index: 3

I10-index: 2